BIAF logo

bioAffinity Technologies, Inc. Stock Price

NasdaqCM:BIAF Community·US$5.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

BIAF Share Price Performance

US$1.23
-27.27 (-95.68%)
US$1.23
-27.27 (-95.68%)
Price US$1.23

BIAF Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate risk with mediocre balance sheet.

5 Risks
0 Rewards

bioAffinity Technologies, Inc. Key Details

US$6.8m

Revenue

US$4.9m

Cost of Revenue

US$1.9m

Gross Profit

US$16.6m

Other Expenses

-US$14.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-3.28
27.86%
-217.50%
2.0%
View Full Analysis

About BIAF

Founded
2014
Employees
57
CEO
Maria Zannes
WebsiteView website
www.bioaffinitytech.com

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Recent BIAF News & Updates

Recent updates

No updates